The present invention provides a vaccine against a coronavirus. According to the present invention, there is provided a peptide consisting of the amino acid sequence set forth in SEQ ID NO: 1 or a partial peptide of a coronavirus spike protein consisting of the amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 1 and a multiple antigen peptide containing a plurality of any of these peptides.

Provided are methods of administering a peptide antagonist of CCAAT/enhancer-binding protein beta (C/EBPβ) and methods of treating solid tumors by administering a peptide antagonist of C/EBPβ.

The present invention concerns a method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein said postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing said at least one bacteriocin and/or endolysin and wherein said postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.

The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.

[Problem] Provided is a cell-penetrating peptide having higher selective toxicity to target cells. Also, provided is a cell-penetrating peptide as an activator delivery carrier.

[Solution] An isolated cell-penetrating peptide comprises a motif selected from the group consisting of RGN, RGH, RYN, LYN, FFN and QYN and a motif selected from the group consisting of NGR and SEQ ID NOs: 44 and 45 and has a β-strand structure between the respective motifs.

[Problem] Provided is a cell-penetrating peptide having higher selective toxicity to target cells. Also, provided is a cell-penetrating peptide as an activator delivery carrier.

[Solution] An isolated cell-penetrating peptide comprises a motif selected from the group consisting of RGN, RGH, RYN, LYN, FFN and QYN and a motif selected from the group consisting of NGR and SEQ ID NOs: 44 and 45 and has a β-strand structure between the respective motifs.

A pharmaceutical composition formulated for delivery of a recombinant adeno-associated virus (rAAV) vector comprising an AAV capsid and a vector genome having human galactosylceramidase (GALC) coding sequence is provided. Also provided are 5 methods and uses of a pharmaceutical composition comprising a rAAV for the treatment of Krabbe disease.

A liquid formulation of a long-acting conjugate of a peptide having activities for a glucagon receptor and a GLP-1 receptor, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 940 nmol/mL of the long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.5 to 7.5, and 1% (w/v) to 20% (w/v) of saccharide, and 0.001% (w/v) to 0.2% (w/v) of a nonionic surfactant.

The present disclosure provides binding agents that modulate the interaction between liver-expressed antimicrobial peptide 2 (LEAP2) and growth hormone secretagogue receptor (GHSR). Specifically, the present disclosure provides binding agents, such as LEAP2 peptides that bind GHSR and methods of their use to treat or ameliorate a neuroendocrine and/or metabolic disease or disorder such as obesity, diabetes, acromegaly, gigantism and/or Prader-Willi syndrome. The present disclosure also provides binding agents, such as antibodies, that bind LEAP2, and methods of their use to, e.g., treat or ameliorate a neuroendocrine and/or metabolic disease or disorder such as cachexia, anorexia, or other wasting syndromes, increase growth hormone levels, or increase GHSR activity.